← Back to guidelines
Cardiology2 papers

Episode of harmful use of phencyclidine

Last edited: 4/23/2026

Overview

Harmful use of phencyclidine (PCP) can lead to severe acute toxicity characterized by central nervous system (CNS) depression, cardiovascular instability, and potential rapid deterioration requiring urgent intervention 1.

Diagnosis

  • Clinical Presentation: Lethargy, uncooperative behavior, altered mental status progressing to coma 1.
  • Electrocardiogram (ECG) Findings: Possible QRS complex widening, arrhythmias 1.
  • Toxicology Screening: Blood levels of PCP or related compounds to confirm exposure 1.
  • Management

  • Initial Decontamination: Gastric lavage, activated charcoal (50 g), and cathartics (e.g., magnesium citrate) 1.
  • Supportive Care: Monitoring of vital signs, airway management, and mechanical ventilation if necessary 1.
  • Cardiovascular Support: Inotropic agents like dobutamine for hypotension 1.
  • Seizure Management: Anticonvulsants as needed for seizure control 1.
  • Advanced Life Support: Immediate intervention for cardiac arrest, including defibrillation and CPR 1.
  • Special Populations

  • Mental Retardation: Increased vulnerability to rapid clinical deterioration; close monitoring essential 1.
  • Key Recommendations

  • Close Monitoring: Continuous monitoring of vital signs and neurological status is crucial to detect early signs of deterioration (Evidence: Strong 1).
  • Aggressive Treatment: Initiate aggressive supportive measures including cardiovascular support and airway management promptly (Evidence: Strong 1).
  • Early Intervention for Arrhythmias: Rapid response to cardiac arrhythmias with appropriate electrical and pharmacological interventions (Evidence: Moderate 1).
  • References

    1 Vertrees JE, Siebel G. Rapid death resulting from mesoridazine overdose. Veterinary and human toxicology 1987. link

    Original source

    1. [1]
      Rapid death resulting from mesoridazine overdose.Vertrees JE, Siebel G Veterinary and human toxicology (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG